Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 374-379

  Herman, Beth D ^b   Fleishaker, Joseph C ^a   Brown, Mark T ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; KETOCONAZOLE; REBOXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG CLEARANCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; ISOMERISM; KETOCONAZOLE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MORPHOLINES; REFERENCE VALUES;

EID: 0032698156     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101207     Document Type: Article

References (18)

1. 1. Melloni P, Carniel G, Della Toree A, Bonsignori A, Buonamici M, Pozzi O, et al. Potential antidepressant agents. α-Aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem Chim Thér 1984;19:235-42.
2. 2. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1989;1:243-53.
3. 3. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998;59(suppl 14):4-7.
4. 4. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8-10.
5. 5. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995;16:443-60.
6. 6. Cocchiara G, Battaglia R, Pevarello P, Strolin-Benedetti M. Comparison of the disposition and of the metabolic-pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991;16:231-9.
7. 7. Wynalda MA, Grossi P, Speed W, Howard MR, Hauer MJ, Wienkers LC. Cytochrome P450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Pharm Sci 1998;1(suppl 1):S-40.
8. 8. Strolin Benedetti M, Frigerio E, Tocchetti P, Brianceschi G, Castelli MG, Pellizzoni C, et al. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 1995;7:285-9.
9. 9. Strolin-Benedetti M, Pellizzoni C, Poggesi I, Dostert P, Dubini A, Bosc M, et al. Pharmacokinetics of reboxetine enantiomers in healthy volunteers [abstract]. Can J Physiol Pharmacol 1994;72(suppl 1):441.
10. 10. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used: therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997;32:357-67.
11. 11. Schafer-Korting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 1993;25:329-41.
12. 12. Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwenbergh G. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract Suppl 1990;71:50-6.
13. 13. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology [review]. Clin Pharmacokinet 1995;29(suppl 1):33-43 [discussion 43-4].
14. 14. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1997;56: 223-31.
15. 15. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions: an update. J Clin Psychopharmacol 1996;16:197-201.
16. 16. Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance. Drug Saf 1996;15:167-75.
17. 17. Fleishaker JC, Mucci M, Pellizzoni C, Poggesi I. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos 1999;20;53-7.
18. 18. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker; 1982.